TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5

被引:32
作者
Karges, B
Krause, G
Homoki, J
Debatin, KM
de Roux, N
Karges, W
机构
[1] Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany
[2] Inst Mol Pharmacol, D-13125 Berlin, Germany
[3] Hop Necker Enfants Malad, INSERM, U584, F-75006 Paris, France
[4] Univ Ulm, Dept Internal Med, Div Endocrinol, D-89081 Ulm, Germany
关键词
D O I
10.1677/joe.1.06208
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mutations of the human thyrotrophin receptor (TSH-R) are a cause of thyroid adenomas and hyperthyroidism. Here we study mechanisms of receptor activation in a genomic TSH-R variant V509A located in transmembrane helix (TMH) 3, which we identify in a family with congenital hyperthyroidism, multiple adenomas and follicular thyroid cancer. Using molecular modelling and dynamic simulation, we predicted the release of amino acid residue A593 (located opposite in domain TMH5) from a tight 'knob-and-hole' interaction with TMH3, physiologically constrained in the native receptor state by the bulky side chain of V509. To experimentally validate this concept, we generated mutant TSH-R expression constructs for functional in vitro studies. TSH-R mutant V509A showed a 2.8-fold increase in basal cAMP production, confirming constitutive TSH-R activation. The addition of a second site suppressor mutant A593V to TSH-R V509A resulted in the normalization of basal cAMP release, and the dose-responsiveness to TSH ligand was maintained. These data thus demonstrate that TSH-R V509A activation is caused by the release of TMH3 - TMH5 interhelical constraints, while the native TSH-R conformation is re-stabilized by the introduction of a spacious valine residue at position 593. In conclusion, we delineate a novel mechanism of constitutive TSH-R activation, leading to thyroid hyperfunction and neoplasia.
引用
收藏
页码:377 / 385
页数:9
相关论文
共 43 条
[1]   A conserved tyrosine residue (Y601) in transmembrane domain 5 of the human thyrotropin receptor serves as a molecular switch to determine G-protein coupling [J].
Biebermann, H ;
Schöneberg, T ;
Schulz, A ;
Krause, G ;
Grüters, A ;
Schultz, G ;
Gudermann, T .
FASEB JOURNAL, 1998, 12 (14) :1461-1471
[2]  
CASE DA, 1998, AMBER 5 0
[3]   Somatic and germline mutations of the TSH receptor and thyroid diseases [J].
Corvilain, B ;
Van Sande, J ;
Dumont, JE ;
Vassart, G .
CLINICAL ENDOCRINOLOGY, 2001, 55 (02) :143-158
[4]   Four families with loss of function mutations of the thyrotropin receptor [J].
deRoux, N ;
Misrahi, M ;
Brauner, R ;
Houang, M ;
Carel, JC ;
Granier, M ;
leBouc, Y ;
Ghinea, N ;
Boumedienne, A ;
Toublanc, JE ;
Milgrom, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (12) :4229-4235
[5]   A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism [J].
DeRoux, N ;
Polak, M ;
Couet, J ;
Leger, J ;
Czernichow, P ;
Milgrom, E ;
Misrahi, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (06) :2023-2026
[6]   GERMLINE MUTATIONS IN THE THYROTROPIN RECEPTOR GENE CAUSE NON-AUTOIMMUNE AUTOSOMAL-DOMINANT HYPERTHYROIDISM [J].
DUPREZ, L ;
PARMA, J ;
VANSANDE, J ;
ALLGEIER, A ;
LECLERE, J ;
SCHVARTZ, C ;
DELISLE, MJ ;
DECOULX, M ;
ORGIAZZI, J ;
DUMONT, J ;
VASSART, G .
NATURE GENETICS, 1994, 7 (03) :396-401
[7]   Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells [J].
Fournes, B ;
Monier, R ;
Michiels, F ;
Milgrom, E ;
Misrahi, M ;
Feunteun, J .
ONCOGENE, 1998, 16 (08) :985-990
[8]   Review of thyroid cancer cases among patients with previous benign thyroid disorders [J].
From, G ;
Mellemgaard, A ;
Knudsen, N ;
Jorgensen, T ;
Perrild, H .
THYROID, 2000, 10 (08) :697-700
[9]   Biological activity of activating thyroid-stimulating hormone receptor mutants depends on the cellular context [J].
Fuhrer, D ;
Alkhafaji, LF ;
Starkey, K ;
Paschke, R ;
Wynford-Thomas, D ;
Eggo, M ;
Ludgate, M .
ENDOCRINOLOGY, 2003, 144 (09) :4018-4030
[10]   Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism [J].
Führer, D ;
Wonerow, P ;
Willgerodt, H ;
Paschke, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (12) :4234-4238